Human CD59 inhibitor sensitizes rituximab-resistant lymphoma cells to complement-mediated cytolysis.
Hu W, Ge X, You T, Xu T, Zhang J, Wu G, Peng Z, Chorev M, Aktas BH, Halperin JA, Brown JR, Qin X. Human CD59 inhibitor sensitizes rituximab-resistant lymphoma cells to complement-mediated cytolysis. Cancer Res. 2011 Mar 15; 71(6):2298-307.
-
Animals
-
Antibodies, Monoclonal, Murine-Derived
-
Antineoplastic Agents
-
Bacteriocins
-
Cell Line, Tumor
-
Complement System Proteins
-
Cytotoxicity, Immunologic
-
Cytotoxins
-
Dose-Response Relationship, Drug
-
Drug Resistance, Neoplasm
-
Flow Cytometry
-
Humans
-
Leukemia, Lymphocytic, Chronic, B-Cell
-
Lymphoma, B-Cell
-
Mice
-
Mice, Inbred BALB C
-
Mice, Knockout
-
Mice, Nude
-
Recombinant Proteins
-
Tumor Cells, Cultured
-
Xenograft Model Antitumor Assays